Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200

This publication has 10 references indexed in Scilit:

• Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab
  Blood, 2002
• Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
  Blood, 2002
• Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies
  Blood, 2002
• Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre study
  British Journal of Haematology, 2001
• Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
  Blood, 2001
• In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
  Blood, 2000
• CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
  Bone Marrow Transplantation, 2000
• Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
  Bone Marrow Transplantation, 2000
• Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT)
  Bone Marrow Transplantation, 2000
• Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases
  Blood, 1998